Compare Natco Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FULFORD INDIA NATCO PHARMA/
FULFORD INDIA
 
P/E (TTM) x 15.6 398.8 3.9% View Chart
P/BV x 3.1 6.2 49.2% View Chart
Dividend Yield % 1.5 0.1 1,719.3%  

Financials

 NATCO PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
FULFORD INDIA
Mar-14
NATCO PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,080942 114.6%   
Low Rs671450 149.2%   
Sales per share (Unadj.) Rs592.1691.4 85.6%  
Earnings per share (Unadj.) Rs188.411.5 1,643.8%  
Cash flow per share (Unadj.) Rs206.315.4 1,343.5%  
Dividends per share (Unadj.) Rs8.252.00 412.5%  
Dividend yield (eoy) %0.90.3 327.9%  
Book value per share (Unadj.) Rs833.6380.0 219.4%  
Shares outstanding (eoy) m36.903.90 946.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.51.0 146.9%   
Avg P/E ratio x4.660.7 7.7%  
P/CF ratio (eoy) x4.245.3 9.4%  
Price / Book Value ratio x1.11.8 57.4%  
Dividend payout %4.417.4 25.1%   
Avg Mkt Cap Rs m32,3112,714 1,190.4%   
No. of employees `0004.80.4 1,088.1%   
Total wages/salary Rs m3,256505 644.8%   
Avg. sales/employee Rs Th4,522.56,073.0 74.5%   
Avg. wages/employee Rs Th674.01,137.4 59.3%   
Avg. net profit/employee Rs Th1,439.0100.7 1,429.4%   
INCOME DATA
Net Sales Rs m21,8482,696 810.3%  
Other income Rs m404125 322.2%   
Total revenues Rs m22,2522,822 788.6%   
Gross profit Rs m9,284-46 -20,008.6%  
Depreciation Rs m66215 4,355.3%   
Interest Rs m15410 1,621.1%   
Profit before tax Rs m8,87254 16,338.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,92010 20,000.0%   
Profit after tax Rs m6,95245 15,552.6%  
Gross profit margin %42.5-1.7 -2,469.4%  
Effective tax rate %21.617.7 122.4%   
Net profit margin %31.81.7 1,919.4%  
BALANCE SHEET DATA
Current assets Rs m21,3071,738 1,225.7%   
Current liabilities Rs m5,920545 1,086.8%   
Net working cap to sales %70.444.3 159.1%  
Current ratio x3.63.2 112.8%  
Inventory Days Days7348 151.1%  
Debtors Days Days1074 2,474.1%  
Net fixed assets Rs m14,98612 125,932.8%   
Share capital Rs m36939 946.2%   
"Free" reserves Rs m30,3531,443 2,103.5%   
Net worth Rs m30,7601,482 2,075.6%   
Long term debt Rs m00-   
Total assets Rs m37,1512,077 1,788.9%  
Interest coverage x58.66.7 872.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.3 45.3%   
Return on assets %19.12.6 732.9%  
Return on equity %22.63.0 749.3%  
Return on capital %29.34.3 681.6%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m10,32217 60,010.2%   
Fx outflow Rs m2,978673 442.5%   
Net fx Rs m7,343-656 -1,119.5%   
CASH FLOW
From Operations Rs m4,63690 5,151.1%  
From Investments Rs m-11,155105 -10,664.4%  
From Financial Activity Rs m6,509-14 -46,163.1%  
Net Cashflow Rs m-18181 -10.0%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 3.8 206.3%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.2 122.6%  
Shareholders   25,395 4,783 530.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 14, 2019 01:17 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - BIOCON COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS